Your email has been successfully added to our mailing list.

×
0 0 0.00049204526816469 -0.0191897654584222 -0.0323109726094801 -0.0257503690339511 -0.0224700672461867 0.023454157782516
Stock impact report

Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology

ARCA biopharma, Inc. (ABIO) 
US:NASDAQ Investor Relations: arcabio.com/investors
Company Research Source: GlobeNewswire
Analysis in full patient cohort shows Gencaro effect compared to standard of careIn the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with metoprolol succinate (TOPROL-XL), experienced: a 36% reduction in cumulative atrial fibrillation burden with a 55% reduction in daily atrial fibrillation burden by the end of the studya 32% reduction in the rate of rhythm control clinical interventions, anda 39% increase in electrocardiograms demonstrating normal sinus rhythm Aspects of these data are the basis for the new patent issued by USPTO for use of Gencaro in treating atrial fibrillation in heart failure patients with ejection fractions greater than 40%, a patient population for whom there are few approved or effective drug therapies WESTMINSTER, Colo., July 28, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies Show less Read more
Impact Snapshot
Event Time:
ABIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
ABIO alerts

from News Quantified
Opt-in for
ABIO alerts

from News Quantified